about
Critical evaluation of gamma-irradiated serum used as feeder in the culture and demonstration of putative nanobacteria and calcifying nanoparticles.Action of Nanoparticles on Platelet Activation and Plasmatic CoagulationCharacterization of biofilm formed by human-derived nanoparticlesBions: a family of biomimetic mineralo-organic complexes derived from biological fluidsNanoparticle size and surface charge determine effects of PAMAM dendrimers on human platelets in vitroDifferential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.Pathological calcification and replicating calcifying-nanoparticles: general approach and correlation.Atherosclerosis and sex hormones: current concepts.Nanodiagnostics, nanopharmacology and nanotoxicology of platelet-vessel wall interactions.Of nanobacteria, nanoparticles, biofilms and their role in health and disease: facts, fancy and future.Serum-derived nanoparticles: de novo generation and growth in vitro, and internalization by mammalian cells in culture.Urokinase-coated chitosan nanoparticles for thrombolytic therapy: preparation and pharmacodynamics in vivo.An Overview of Nanoparticle Based Delivery for Treatment of Inner Ear Disorders.Hydroxyapatite as a Vehicle for the Selective Effect of Superparamagnetic Iron Oxide Nanoparticles against Human Glioblastoma Cells.A rapid screening method to evaluate the impact of nanoparticles on macrophages.Development and haematotoxicological evaluation of doped hydroxyapatite based multimodal nanocontrast agent for near-infrared, magnetic resonance and X-ray contrast imaging.Vascular biosafety of commercial hydroxyapatite particles: discrepancy between blood compatibility assays and endothelial cell behavior.
P2860
Q33570438-FF3B7879-B444-4B37-B125-46A4315061D6Q33600393-85A20D38-C20B-4EBC-989F-0971BAE74A81Q34505074-A2FFFF39-0DC8-41AF-ADE2-7FA1086FFBDFQ35005673-3F593ACC-4BAA-4EF3-9025-E976A5E850BBQ36760929-4C60BE71-012D-4765-A25A-2017C89DD447Q36807581-E992BC02-57BE-4FE7-8CF7-B795C937FFA2Q37679688-3608D024-6005-46DE-A5C0-C837EE189CE8Q37801387-A553BD23-5E42-4F68-A359-B0480E7DD920Q38495085-02E06FFA-B023-48F5-9862-5D8D9AA68E4EQ39200253-BCD0160F-E325-4A8B-AB20-A192439ACAFCQ39555766-C0F10E2E-652B-4119-B3CC-9196C8B438EFQ44949624-C6678EDD-D22F-44EF-B03F-B9C0F3260AF3Q45887696-34255E38-54AA-47D9-8314-2334BF057C14Q46277468-8A30D711-BA82-4973-AB49-B3E0F944972FQ48285320-CB4CE94F-6B99-46F9-9A7F-728C9EBC7206Q50516003-108D9A81-4038-4EFC-9D10-34FB81F71DCEQ51732274-6968BD71-3C5E-45B8-AC93-BD00B9CEEA64
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biologic nanoparticles and platelet reactivity
@en
Biologic nanoparticles and platelet reactivity.
@nl
type
label
Biologic nanoparticles and platelet reactivity
@en
Biologic nanoparticles and platelet reactivity.
@nl
prefLabel
Biologic nanoparticles and platelet reactivity
@en
Biologic nanoparticles and platelet reactivity.
@nl
P2093
P2860
P356
P1433
P1476
Biologic nanoparticles and platelet reactivity
@en
P2093
John C Lieske
Larry W Hunter
Muthuvel Jayachandran
Phillip D Squillace
Virginia M Miller
Vivasvat Kaul
P2860
P304
P356
10.2217/NNM.09.61
P577
2009-10-01T00:00:00Z